Jonathan Ingles: Ben — before we get into any of the arguments, I want to just say the fact out loud, because I think it gets buried. A child with cancer signed her name on the side of a SpaceX Falcon 9 rocket. That happened today.
Ben Okonkwo: Hm. Today being July 25th, 2026 — the day MrBeast's video dropped.
Jonathan Ingles: 'I Helped 100 Kids Fight Cancer.' That's the title. Jimmy Donaldson, 500 million subscribers. The donation structure: six-point-five million dollars, split across Beast Philanthropy, Amgen, and the St. Baldrick's Childhood Cancer Research Foundation, directed to Stand Up To Cancer for a new SU2C Pediatric Cancer Dream Team.
Ben Okonkwo: Three co-funders, one announcement, and we still don't have the breakdown of who gave what — but okay, we'll get to that.
Jonathan Ingles: We will. But look — LeBron James, Akron, the LeBron James Family Foundation. Thirty kids to Disney World. Swimming with a whale shark. And then a Falcon 9.
Ben Okonkwo: The production scale is genuinely hard to categorize. I don't have a clean frame for it yet.
Jonathan Ingles: That's exactly the question. Picture it: a kid who's been through chemo writes her name on a rocket that's going to space. That's what 500 million people are watching. Figure out what you think about that first — then we'll do the analysis.
Ben Okonkwo: Right — but the framing around that production scale is doing something specific. Think about three people at a restaurant. They all put in money for the bill. But one person stands up and takes the bow, and the other two just quietly slide their cards across the table. That's the attribution structure here. Beast Philanthropy, Amgen, St. Baldrick's — all three committed to this $6.5 million. Nearly every headline reads: 'MrBeast donates $6.5 million.' The three-way structure is just... gone.
Jonathan Ingles: And we don't even have the split. Who gave what — that number has not been reported.
Ben Okonkwo: That's the load-bearing missing fact. Now, Amgen is a biotech company — they work on cancer drugs. So the question of whether this is philanthropy or a co-branding exercise aligned with their commercial interests is not a small question. And here's the part that makes it stranger: what I've found suggests their involvement here is pre-competitive research, meaning competing pharma companies access the same findings. Amgen doesn't typically benefit directly from pediatric cancer work the way they would from adult oncology. So why is a drug company funding something where they don't capture the upside?
Jonathan Ingles: They capture the upside that isn't in the research. They get the moral credibility of cancer kids without anyone scrutinizing their drug pricing. That's the transaction.
Ben Okonkwo: Okay — I think that's probably directionally right, actually, but I want to be careful. We don't have confirmed splits, we don't have Amgen's internal rationale. The structure is documented. The motive is inference. Those are different things.
Jonathan Ingles: Fair. The structure alone is enough. And look — Beast Philanthropy has a track record here: a thousand cataract surgeries, a hundred wells in Africa, a clinic for kids rescued from slavery. That's real. But whether this specific model actually accelerates pediatric oncology outcomes — and whether Amgen's invisibility was strategic — that's what we need to sit with. And the exploitation argument cuts right across this whole thing, which we'll get to — because the rebuttal that calls critics out for 'moral dumbfounding' either lands or it doesn't.
Ben Okonkwo: And that exploitation take — that's actually where the peer-reviewed record gets interesting, because it's not settled. Jeremy Snyder published in the Journal of Medical Ethics in December 2025 — formal academic critique, not Twitter — arguing MrBeast's model risks exploiting vulnerable recipients, undermining systemic giving, creating moral licensing in audiences. That's a real argument.
Jonathan Ingles: It's real, but it got a formal rebuttal. Same journal. March 2026. Michał Białek at the University of Wrocław publishes a peer-reviewed response calling the outrage 'moral dumbfounding.' Critics are certain something is wrong but cannot name an ethical principle that distinguishes this from traditional philanthropy. That's the charge.
Ben Okonkwo: Which is — okay, that's pointed. But 'you can't articulate the harm' doesn't mean there isn't one.
Jonathan Ingles: No, but it does mean the exploitation framing is not the slam dunk people are treating it as online. Dwayne Johnson, IShowSpeed, KSI, Dr. Mike Varshavski — that cast intensifies the spectacle critique, sure. But Dr. Alan Wayne — a physician — says shared memories and experiences are part of comprehensive cancer treatment for children. That's not a YouTuber talking. That's a doctor saying the Disney World trip isn't pure spectacle.
Ben Okonkwo: Right — but the conflict-of-interest edge is the part I can't resolve. Five hundred million subscribers means this video is also growing MrBeast's brand, his ad revenue. Those things happen simultaneously. And I haven't seen anyone separate those revenue streams from the donation amount.
Jonathan Ingles: Frankly, that's true of almost every celebrity philanthropist. The attention economy is the mechanism. You can't use it and then pretend you're not using it — but the kids still went to Disney World.
Ben Okonkwo: So the exploitation framing probably overstates it, but 'moral dumbfounding' might understate the conflict. Neither answer is clean.
Jonathan Ingles: The thing I keep sitting with — the SU2C Pediatric Cancer Dream Team is a real structure, the $6.5 million lands in actual research, fine. But there's no track record. This model hasn't been run in pediatric cancer before. So we're funding an organizational experiment and calling it a breakthrough.
Ben Okonkwo: And the video dropped July 25th. The narrative — whether 'spectacle works' or 'spectacle exploits' — that calcifies years before any outcome data from the Dream Team exists. That's the actual problem. Not the ethics debate. The timing.
Jonathan Ingles: So who measures it? And honestly — will anyone believe the measurement when it comes? If Amgen funds the evaluation of research Amgen co-funded...
Ben Okonkwo: I don't have an answer to that. I genuinely don't.
